Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Berberine Effects on Clinical Symptoms and Metabolic Disturbance as an Adjunctive Therapy in Patients With Schizophrenia: a Randomized Double-blind Placebo-controlled Study

NCT03548155 is registered in ClinicalTrials.gov with Tianjin Anding Hospital as lead sponsor.

NCT NCT03548155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03548155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Berberine Effects on Clinical Symptoms and Metabolic Disturbance as an Adjunctive Therapy in Patients With Schizophrenia: a Randomized Double-blind Placebo-controlled Study
Lead sponsor
Tianjin Anding Hospital
Phase
Not applicable
Overall status
Completed
Start date
July 24, 2014
Completion date
May 8, 2017
Enrollment
65 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia, therapeutics